HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, announces a management-led majority stake acquisition by a syndicate of globally recognized private and public investors, including K5 Global, Bezos Expeditions, Wellington Management and other new and existing investors. The transaction values HistoSonics at approximately $2.25 billion and positions the company for accelerated growth of the Edison System across new clinical indications and global markets. HistoSonics, founded in 2009, received FDA De Novo clearance in October 2023 and uses non-invasive focused ultrasound energy to mechanically destroy and liquify targeted tissue and tumors at a sub-cellular level and without the invasiveness or toxicity of traditional procedures.
Read the full article: HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors //
Source: https://www.businesswire.com/news/home/20250807749442/en/HistoSonics-Announces-%242.25B-Acquisition-by-Consortium-of-Top-Tier-Investors